InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research report sent to investors on Friday morning. The firm issued a sell rating on the stock.

InspireMD Stock Up 3.8 %

NSPR stock opened at $2.75 on Friday. The business’s fifty day simple moving average is $2.70 and its two-hundred day simple moving average is $2.50. InspireMD has a twelve month low of $1.81 and a twelve month high of $3.85. The firm has a market cap of $68.56 million, a price-to-earnings ratio of -3.62 and a beta of 0.96.

InspireMD (NYSE:NSPR) last released its earnings results on Tuesday, August 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). InspireMD had a negative return on equity of 62.02% and a negative net margin of 388.67%. The business had revenue of $1.74 million during the quarter, compared to analysts’ expectations of $1.74 million. During the same quarter in the previous year, the business earned ($0.24) EPS. Research analysts expect that InspireMD will post -0.82 EPS for the current year.

Hedge Funds Weigh In On InspireMD

Several institutional investors have recently made changes to their positions in the company. Rosalind Advisors Inc. boosted its position in InspireMD by 266.4% during the second quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock valued at $6,272,000 after purchasing an additional 1,827,579 shares in the last quarter. Mesirow Financial Investment Management Inc. bought a new stake in InspireMD during the first quarter valued at about $71,000. Finally, McKinley Carter Wealth Services Inc. bought a new stake in InspireMD during the fourth quarter valued at about $28,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.